Abstract:Over the past decade, in vivo gene replacement therapy has significantly advanced, resulting in market approval of numerous therapeutics predominantly relying on adeno‐associated viral vectors (AAV). While viral vectors have undeniably addressed several critical healthcare challenges, their clinical application has unveiled a range of limitations and safety concerns. This review highlights the emerging challenges in the field of gene therapy. At first, we discuss both the role of biological barriers in viral gene therapy with a focus on AAVs, and review current landscape of in vivo human gene therapy. We delineate advantages and disadvantages of AAVs as gene delivery vehicles, mostly from the safety perspective (hepatotoxicity, cardiotoxicity, neurotoxicity, inflammatory responses etc.), and outline the mechanisms of adverse events in response to AAV. Contribution of every aspect of AAV vectors (genomic structure, capsid proteins) and host responses to injected AAV is considered and substantiated by basic, translational and clinical studies. The updated evaluation of recent AAV clinical trials and current medical experience clearly shows the risks of AAVs that sometimes overshadow the hopes for curing a hereditary disease. At last, a set of established and new molecular and nanotechnology tools and approaches are provided as potential solutions for mitigating or eliminating side effects. The increasing number of severe adverse reactions and, sadly deaths, demands decisive actions to resolve the issue of immune responses and extremely high doses of viral vectors used for gene therapy. In response to these challenges, various strategies are under development, including approaches aimed at augmenting characteristics of viral vectors and others focused on creating secure and efficacious non‐viral vectors. This comprehensive review offers an overarching perspective on the present state of gene therapy utilizing both viral and non‐viral vectors.

Changing trends in the development of AAV-based gene therapies: a meta-analysis of past and present therapies

The clinical landscape for AAV gene therapies

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

AAV-based in vivo gene therapy for neurological disorders

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Bibliometric analysis of global research trends in adeno-associated virus vector for gene therapy (1991-2022)

Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Adeno-associated virus vector as a platform for gene therapy delivery

Adeno-Associated Virus (AAV) as a Vector for Gene Therapy

Adeno-associated viral vectors for correction of inborn errors of metabolism: progressing towards clinical application.

Adeno-associated virus therapies: Pioneering solutions for human genetic diseases

The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution

Various AAV Serotypes and Their Applications in Gene Therapy: An Overview

AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges

Engineering adeno-associated virus vectors for gene therapy

Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression

Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies

Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives